Aerospan HFA Alternatives Compared
| Aerospan HFA (flunisolide) | Dupilumab | Montelukast |
|
|---|
| Aerospan HFA (flunisolide) | Dupilumab | Montelukast |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Asthma. Aerospan HFA may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Eosinophilic Esophagitis, Chronic Rhinosinusitis With Nasal Polyps, Eczema, Prurigo Nodularis, Asthma - Maintenance, Atopic Dermatitis, Asthma, COPD. Dupilumab may also be used for... View more |
Prescription only
Montelukast is an oral medication that is usually taken daily for the maintenance treatment of asthma or allergic rhinitis. It will not relieve an acute asthma attack and some people may experience... View more |
Related suggestions |
|||||||
| More about Aerospan HFA (flunisolide) | More about Dupilumab | More about Montelukast | ||||||||
| Ratings & Reviews | ||||||||||
|
Aerospan HFA has an average rating of 10.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Dupilumab has an average rating of 7.2 out of 10 from a total of 506 ratings on Drugs.com. 60% of reviewers reported a positive effect, while 21% reported a negative effect. |
Montelukast has an average rating of 5.6 out of 10 from a total of 570 ratings on Drugs.com. 42% of reviewers reported a positive effect, while 41% reported a negative effect. |
||||||||
| Drug Class | ||||||||||
| Side Effects | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
Lower cost generic |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Montelukast prices |
||||||||
| Dosage Forms Available | ||||||||||
|
N/A |
|
||||||||
| Brand Names | ||||||||||
|
N/A |
Dupixent | Singulair | ||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
|
1.8 hours |
N/A |
5.5 hours |
||||||||
| CSA Schedule ** View glossary of terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 61 drugs are known to interact with Aerospan HFA:
|
A total of 89 drugs are known to interact with Dupilumab:
|
A total of 113 drugs are known to interact with Montelukast:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
January 27, 2006 |
N/A |
N/A |
||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.